🔗 Share this article

A shadow economy for unapproved slimming medications is being driven by social media fitness personalities and vendors on communication apps, based on recent findings.

Experimental Drug Gaining Popularity Online

The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its supposed fat-burning effects. Viewers are urged to message these accounts privately for supplier links, while also obtaining promotional offers.

Thriving Commerce on Messaging Platforms

Separately, a flourishing trade exists on messaging services, where communities with thousands of members share comparison photos, injection guides and assertions of rapid British shipping. Sellers market the drug there before redirecting customers to WhatsApp for purchases.

Learning About The Experimental Drug

Retatrutide is an experimental injection developed by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could assist individuals reduce up to 25% of their total weight. Nicknamed the “triple G”, the substance is being hailed online as the successor to Ozempic.

Medical Experts Express Worries

However, physicians and pharmacists have cautions that the distribution of what remains an unapproved drug in the UK is a cause for concern and could lead to individuals injecting products of uncertain source.

Several professionals said the demand for retatrutide could be linked to the increasing cost of approved weight loss products such as Mounjaro.

Regulatory Position and Implementation

Marketing the unapproved drug on social media or Telegram is illegal in the UK, as it is an unlicensed drug that cannot be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.

Several influencers attempt to sidestep the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and distribution can still violate medicines, advertising, and customer regulations, potentially leading to penalties, legal action or prison.

Platform Reaction and Content Elimination

According to the social media company, the platform has removed problematic content and banned related keywords and query recommendations. The company stated it was committed to keeping the service safe and allocating resources in enhancing enforcement strategies.

Online Marketplace Operations

Research also found groups with up to nine thousand participants selling retatrutide using the platform's integrated discovery tool, which operates like a public directory. Typing “retatrutide” immediately displays groups with numerous of members, populated with images of weight loss, positive testimonials and detailed guides for mixing or administering at home.

After moments of entering one community, a seller shared contact information, where most purchases occur. The vendor provided an instruction manual and promised delivery within 48 hours. When asked whether the product was genuine, one seller responded: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. Not one inquired about weight, health issues or past usage.

Item Information and Costs

Inside these groups, posts show black plastic packages with Royal Mail stickers, stating to contain new batches. One communication read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, mixed at home with purified liquid, or pre-filled pens usually priced at 160 pounds for 20 milligrams. When asked how much time a pen should be used, vendors give conflicting responses ranging from a several days to “depends on your body”.

Platform Moderation and Security Measures

A representative for Telegram said it actively monitored harmful content on its service including content that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“People are administering substances they can’t verify. Although the science behind this drug is sound, these online products may not include what they advertise,” stated a pharmacy expert, the director of pharmacy at Chemist4U.

A medical professional of Asda Online Doctor linked the increase in demand to current cost increases for authorized weight-loss medications such as Mounjaro. “With prices rising, patients are turning to social media. But counterfeit treatments are highly risky. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she said.

Her staff has already seen patients injured by personal administration from unconfirmed suppliers. “We understand the frustration, but purchasing from messaging apps or WhatsApp is taking chances with your health,” said Wyllie. “These materials could be impure or incorrectly dosed.”

Producer Statement

A spokesperson from Eli Lilly stated the substance was in third stage research studies and had not been reviewed or approved by any regulatory agency globally. “Therefore at this time no one can market [it] for human use,” they explained, adding that any item “falsely representing itself as a company experimental substance not yet authorized … may expose users to possibly serious health risks”.